-
Mashup Score: 6
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, Study Population, Human, Measurable Residual Disease 1 Division of Hematology Oncology, University of Virginia, Charlottesville,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Paper: A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma - 7 hour(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Drug development, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events, Study Population, Human, Measurable Residual Disease Peter T. Tan, MBBS 1, LI Bao 2 *, Qingsong Yin, PhD 3 *, Chunrui Li 4 *, Sorab
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma. N=40, ORR: 39%, ORR 92% in patients receiving >120 mg dose; CRS (gr1-2): 25% #mmsm #bmtsm https://t.co/kjcnUGDhL7
-
-
Mashup Score: 16
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions Hematology Disease Topics & Pathways: Research, Clinical trials, Combination therapy, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease Elias K. Mai, MD 1 *, Hans Salwender, MD 2 *, Michael Hundemer, MD 3 *, Uta Bertsch,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 GMMG-HD7 Trial (Isa-VRd vs. VRd induction) -More pts achieved MRDneg and continued MRDneg with Isa-VRd -Pts with MRDneg and continued MRDneg had longer PFS regardless of the induction arm #mmsm #bmtsm @EliasKarlMai https://t.co/hmsBhPnfK5
-
-
Mashup Score: 9
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice Hematology Disease Topics & Pathways: Research, Clinical Research, Plasma Cell Disorders, Diseases, Real-world evidence, Lymphoid Malignancies, Measurable Residual Disease 1 Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan 2 Department of Radiology, Kameda Medical Center, Chiba, JPN
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 High total diffusion volume (tDV) by whole-body MRI correlates with shorter PFS, even in patients with MRD negative BM. -Combined BM MRD and WB MRI may optimize the response assessment #mmsm #bmtsm https://t.co/8jqgnOSOh5
-
-
Mashup Score: 8Paper: A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma - 7 day(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice Hematology Disease Topics & Pathways: Research, Clinical Research, Diseases, Measurable Residual Disease Ioannis Ntanasis-Stathopoulos, MD, PhD, MSc 1 *, Ioannis V Kostopoulos, PhD 2 *, Panagiotis Malandrakis, MD 1 *, Pantelis Rousakis, Msc. 3 *, Chrysanthi Panteli 3 *, Evangelos Eleutherakis-Papaiakovou, MD 1
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 A Novel Prognostic System Based on Circulating Tumor Cells (CTC) for NDMM -Elevated CTC (cutoff 0.02) is an independent adverse prognostic factor for NDMM #mmsm #bmtsm https://t.co/R4LCpxyi37
-
-
Mashup Score: 12Paper: Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis - 7 day(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice Hematology Disease Topics & Pathways: Measurable Residual Disease Noemi Puig, PhD 1,2, Cristina Agullo 2 *, Bruno Paiva, PhD 3,4,5,6 *, María T Cedena 7 *, Laura Rosiñol Dachs 8,9,10 *, Teresa Contreras 11 *, Joaquín Martínez-Lopez 12,13 *, Albert Oriol 14,15 *, María-Jesús Blanchard, MD, PhD 16,17 *, Rafael
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Reevaluating the IMWG MM CR Criteria with Mass Spectrometry (MS) -MS surpasses the clinical value of BM PC% and sIFE -Study suggests that BM aspirate is only needed for MRD assessment #mmsm #bmtsm @NoemiPuig2 @mvmateos @BrunoPaiva_UNAV https://t.co/CTUMNyiJtu
-
-
Mashup Score: 2
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice Hematology Disease Topics & Pathways: Research, Clinical trials, Translational Research, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Luca Bertamini, MD 1 *, Cathelijne Fokkema, MD 1 *, Paula Rodríguez-Otero, MD, PhD 2 *, Mark van Duin, PhD 1 *, Niels W.C.J. Van De Donk, MD 3, Mattia
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Circulating Tumor Cells (CTC) as a biomarker for TE NDMM in Perseus trial (D-VRd vs. VRd) -CTC is an independent prognostic factor -HR cytogenetics + CTC => dismal outcome #mmsm #bmtsm @LucaBertamini @CathelijneF7 https://t.co/X49hme5wYY
-
-
Mashup Score: 16
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions Hematology Disease Topics & Pathways: Research, Clinical trials, Combination therapy, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease Elias K. Mai, MD 1 *, Hans Salwender, MD 2 *, Michael Hundemer, MD 3 *, Uta Bertsch,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 GMMG-HD7 Trial (Isa-VRd vs. VRd induction) -More pts achieved MRDneg and continued MRDneg with Isa-VRd -Pts with MRDneg and continued MRDneg had longer PFS regardless of the induction arm #mmsm #bmtsm @EliasKarlMai https://t.co/hmsBhPnfK5
-
-
Mashup Score: 16
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality) Kritika Yadav, MD 1 *, Tanvi H. Patel, MD 2 *, Ramya Bachu, MD 2 *, Jean Esselmann, RN 3 *, Lisa E Rein, ScM 4 *, Aniko Szabo, PhD 5 *, Abhishek Janardan, MD 6 *, Evanka Annyapu, BS 7 *, Catherine E. Skoog, PA 8 *, Areyl Goff, MSN, RN, NP
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) post anti-BCMA CAR-T for MM. N=22; significant improvement in cytopenia at 3 and 6-month post CAR-T #mmsm #bmtsm @MeeraMohanMD @adsouza_md https://t.co/eB2AFQahhT
-
-
Mashup Score: 70
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions Hematology Disease Topics & Pathways: Research, Clinical Research, Measurable Residual Disease Panagiotis Malandrakis, MD 1 *, Ioannis Ntanasis-Stathopoulos, MD, PhD, MSc 1 *, Ioannis V Kostopoulos, PhD 2 *, Vasiliki Spiliopoulou, MD 1 *, Despina Fotiou, MD 1 *, Foteini Theodorakakou, MD 1 *, Magdalini
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Sustained MRD negativity for 3 years can guide discontinuation of Len maintenance after ASCT in MM. 92% patients remained MRD-ve 30 months after maintenance discontinuation #mmsm #bmtsm @thanosdimop https://t.co/1mGjjx3JaI
-
#ASH24 Dara-Len vs. Len maintenance in NDMM, MRD+ post ASCT (AURIGA trial). N=200, higher MRD (10^-5 NGS) and PFS with Dara-Len. Higher gr 3/4 TEAE with Dara-Len #mmsm #bmtsm @ldandersonjr https://t.co/jfvL4Pi0Dj